Press Releases

Upcoming Events

ASM/ESCMID Conference on Drug Development 2019
Tuesday, September 03 - Friday, September 06

Boston, MA

CARB-X Product Developer Conference
Friday, September 06

Boston, MA

> See all Events
August 21, 2019

VenatoRx Pharmaceuticals added pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta, to its development team. These appointments come as the Company continues to advance its portfolio of antibacterial and antiviral assets through their respective pre-clinical and clinical milestones.

August 06, 2019

VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal for the second year in a row. Headquartered in the Philadelphia suburbs of Malvern, Pennsylvania, VenatoRx has nearly doubled its headcount over the past year and is actively seeking motivated, passionate and entrepreneurial-minded professionals for open positions in Quality Assurance, Operations, Discovery, and Development to support its aggressive strategic growth plan.

July 22, 2019

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will collaborate with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and VenatoRx Pharmaceuticals, Inc. of Malvern, Pennsylvania, to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available agents.

June 20, 2019

VenatoRx Pharmaceuticals' founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.

June 17, 2019

VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. VenatoRx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.

April 10, 2019

VenatoRx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring cefepime/VNRX-5133 and ceftibuten/VNRX-7145.

April 04, 2019

Dr. Wittmer has more than 20 years’ experience and a demonstrated track record in leading development from early stages through to licensing, registration and commercialization of new therapeutics. In her role at VenatoRx, Dr. Wittmer will oversee nonclinical and clinical development, as well as global regulatory affairs.

March 25, 2019

President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.

Archive: 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010